Background: Although BRAF and RAS mutations in radically resected pts with stage I- II and III melanoma could have a prognostic value, conflicting evidences are still available. The present retrospective study was aimed to investigate this controversial issue. Methods: We retrospectively evaluated a consecutive series of 201 pts with stage I-III melanoma (AJCC 8th) who have undergone radical surgery from 2005 and 2010. For each pt we retrieved the clinical record and collected data concerning the clinical history. In addition, we evaluated the mutation status of somatic BRAF, KRAS and NRAS on a tissue sample obtained from primary surgery material. We describe the expression rate of such mutations and their relationship with pts’ survival outcomes. Results: To date they are evaluable data on 100 pts (M/F 62/38): the median age was 66 yrs (range 36-91), most of the pts was in stage I-II (66 %). The detected mutations is described in the table. Conclusions: From our preliminary results, it appears that BRAF and RAS mutations did not have prognostic value in the assessed population. The final report of the analyses carried on the whole population will increase the study ability to assess the role of these mutations in predicting the outcomes of radically resected stage I-III melanoma.